Twenty-one patients with advanced prostatic adenocarcinoma previously untreated with conventional endocrine therapy were treated with an oral non-steroidal antiandrogen, flutamide. There were 19 favorable responders, 1 failure and 1 equivocal response. Flutamide seems to be a safe antiandrogen, which is effective in the management of previously untreated patients with advanced prostatic carcinoma.
No takes yet. Share an insight, caveat, or question.
Sogani et al. (1979) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: